Drug Profile
Research programme: antibacterials therapeutics - Debiopharm Group/TCG Lifesciences
Alternative Names: Debio 1348Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Debiopharm Group
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Nosocomial infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Nosocomial-infections(Treatment-resistant) in India
- 10 Sep 2013 Early research in Nosocomial infections (treatment-resistant) in India (unspecified route)